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Abstract Asthma is a chronic inflammatory disorder ofthe airways that has a considerable socioeconomic impact. 
Asthma management guidelines have been introduced to help provide better long-term control of asthma. Although 
recommended guidelines may increase the direct medication costs, the overall direct costs of asthma may be reduced 
due to fewer exacerbations. In addition, indirect costs due to lost productivity and mortality are reduced and patients 
have an improved quality of life. Inhaled corticosteroids are first-line therapy in the treatment of persistent asthma. 
Againstthis background, we have assessed the cost-effectiveness of Symbicort@ (budesonide and formoterol in a single 
inhaler), atreatmentthat provides better control of asthma compared with budesonide alone.While the prescribing costs 
of Symbicort@ were found to be higher than for budesonide alone, these were partially offset by reduced costs due to 
fewer asthma exacerbations and a reduced need for other medicationsCombined long-term therapy with budesonide 
and formoterol also improves patient quality of life compared with budesonide alone.Two other factors associated with 
asthma treatment success and cost-effectiveness are patient/physician education and good patient adherence to pre- 
scribed therapy The introduction of a single inhaler that is easy to use in simple treatment regimens may improve patient 
adherenceto prescribed medication, thus resulting in improved asthmacontrol and fewerexacerbations.Treatment with 
Symbicort@ is more cost-effective than treatment with budesonide alone. 
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INTRODUCTION 
Asthma is a common and chronic inflammatory disorder 
of the airways that has increased in prevalence (I) and 
cost (2). Asthma not only has a social impact on patients 
and their families, but also places a considerable 
economic burden on healthcare resources in developed 
countries (3,4). In particular, poorly controlled asthma 
can greatly reduce patient quality of life and incur avoid- 
able costs. 
Asthma treatment guidelines have been introduced 
to improve the quality of asthma patient care with 
the aim of providing better asthma control (5-8). 
Current treatment options in all but intermittent 
cases of asthma include inhaled corticosteroids to 
control the underlying inflammation together with 
inhaled bronchodilators to relieve the symptoms of 
asthma (5-8). In those patients whose asthma remains 
inadequately controlled with inhaled corticosteroids, 
guidelines recommend increasing the dose of the co- 
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rticosteroid in a stepwise fashion or adding a long-acting 
Pz-agonist or additional drugs to the treatment 
regimen (78). The guidelines also recommend that 
a short-acting Pz-agonist should be prescribed as 
needed. 
The costs of asthma are increasing and there is in- 
creasing pressure on physicians to make the most cost- 
effective choices in the management of this disease. 
Cost-effectiveness is the relationship between total 
costs of a specified treatment and the health outcome 
achieved by that treatment. The total costs associated 
with asthma therapy are far-reaching and can be difficult 
to calculate.Total costs can be separated into direct, in- 
direct and intangible costs (9).The direct costs of asthma 
are the most straightforward to understand and to cal- 
culate; they are the health service costs associated with 
the diagnosis, assessment and treatment of the disease 
and include the costs of medications, hospitalization, 
emergency care, medical consultations, lung function 
tests, peak flow meters, chest X-rays, etc.They also in- 
clude costs incurred by the patient for travelling and 
waiting to attend consultations, and for special diets or 
appliances.The indirect costs are those costs that are as- 
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sociated with lost productivity by the patient due to days 
off work, under-performance at work, premature retire- 
ment or death, or adverse effects of asthma medications. 
Parents often have to take time off work to care for an 
asthmatic child and these costs should also be included as 
indirect costs. Such indirect costs can be difficult to esti- 
mate accurately. Intangible costs are the most difficult to 
calculate as they relate to the personal and emotional con- 
sequences of having asthma and include diminished quality 
of life, psychological effects, social costs and asthma- 
related ‘pain and suffering’, all of which can restrict the 
patient from leading a normal active life. Intangible costs 
are rarely included in studies of the economic impact of 
asthma. Thus the total cost of asthma treatment can be 
reduced by reducing either the direct or indirect costs 
or both. 
It has been suggested that if asthma is managed appro- 
priately such that patients have optimal control of their 
asthma, then the socioeconomic burden of asthma for 
society should be reduced (9). To optimize asthma con- 
trol, all aspects of asthma care need to be consider- 
ed-from treatment options and costs of treatment to 
appropriate asthma education for patients and their 
carers. To this end, if the direct cost of medication or 
education is increased the treatment may still be consid- 
ered cost-effective if the benefits of the treatment in 
terms of health outcomes and reduction in total costs 
outweigh the original increase in cost.This paper will re- 
view these aspects of asthma care with particular refer- 
ence to Symbicort@, the new combination of the inhaled 
glucocorticosteroid, budesonide, and the inhaled long- 
acting fiz-agonist, formoterol, delivered by a single in- 
haler. 
THE ECONOMIC BURDEN OF 
ASTHMA 
The high and increasing prevalence and morbidity of 
asthma place a huge burden on healthcare resources. In 
particular, asthma is a common cause of hospital ad- 
mission among children, and the annual healthcare costs 
of childhood asthma in the UK have been estimated at 
between &IO0 million and &I50 million (lO).The economic 
impact of asthma has been studied in several countries in 
an attempt to identify areas where resources may be 
saved. A study conducted in Sweden reported that, in 
1991, the direct (37%) and indirect (63%) costs of asthma 
amounted to a total of (Swedish krona) SEK 3 ‘0 billion (I 
SEK=O ‘09 US$), approximately I% of the costs of all dis- 
eases (II). In another report (12), more than half of the 
total cost of asthma in the USA (54%) and Australia 
(77%) was associated with direct costs for medical treat- 
ment whereas in Sweden the direct costs (43%) were 
lower than the indirect costs (57%). This difference ap- 
pears to be largely due to a higher proportion of in- 
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patient and emergency care costs in the USA and Aus- 
tralia compared with Sweden (12). A comparison of the 
cost of asthma per affected individual per year in six 
countries is shown in Figure I. The costs ranged from 
US$326 to 1315 per year. 
Drug costs make up the single largest component of 
direct costs of asthma (usually 30-40%) and are the 
major cost among patients with mild to moderate asth- 
ma (4). The cost of treating patients with asthma in- 
creases according to the degree of disease severity, and 
is greatest in the relatively small proportion of patients 
with severe asthma (12). In Spain, Serra-Batlles et al. (13) 
found that the total costs of asthma for patients with 
moderate disease were almost twice as high as those 
with mild asthma, whereas patients with severe asthma 
were almost five times as costly as those with mild asth- 
ma. Hospitalization costs are the major cost in patients 
with severe asthma. Thus, there is considerable interest 
in the potential to reduce the high medical costs of asth- 
ma by reducing the riskof hospitalization through better 
asthma control. This approach may also reduce the in- 
direct and intangible costs of asthma by reducing the 
number of days absent from school or work and offering 
the patient a better quality of life. 
Although each asthma case is different, guidelines have 
been introduced to help physicians in their diagnosis and 
choice of therapy, and it is important that these recom- 
mendations for asthma management are put into prac- 
tice. Studies have shown that when asthma patients are 
treated with anti-inflammatory drugs according to the 
guidelines, their long-term health outcome is better and 
the treatment is also cost-effective (14). Although the 
widespread use of anti-inflammatory drugs results in in- 
creased medication costs, these are more than offset by 
reductions in emergency room visits and hospitaliz- 
ations, thus reducing the overall healthcare costs. A re- 
cent study in the UK estimated that the annual 
prescribing costs for adult asthma treatment could rise 
by nearly 30%, from 5388 million to a possible &533 mil- 
lion, if the guidelines were followed more stringently (l5), 
Australia New South Canada Sweden UK USA 
W&S, 
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Figure 1. Comparison ofthe cost of asthma per affected indi- 
vidual (adjusted to 1991 US dollars) [datafrom Sullivan 1998 (l2)]. 
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However, there is increasing evidence that asthma treat- 
ment guidelines are not being followed by physicians 
(16,17). in addition, many patients do not take their treat- 
ment as prescribed (18). As a result, large numbers of 
patients have poorly controlled asthma, which leads to 
an increased risk of attacks or exacerbations of asthma, 
some of which require hospitalization-the most costly 
component of asthma care. In a recent study by Anders- 
son et al., the mean total cost of a mild exacerbation in 
the UK in 1999 was reported to be &57 (95% confidence 
interval [Cl]: 27; 96) compared with ~!Z377 (95% Cl: 321; 
452) for a severe exacerbation (19). In another study in 
the UK involving over 17000 adult asthmatics, it was re- 
ported that almost 50% of the patients were being un- 
der-treated; they should have been treated at a step 
higher to be in accordance with the British Thoracic 
Society (BTS) Guidelines (5). Although patients at any 
step of the guidelines are at risk of having an asthma at- 
tack, the risk increases as the severity of the asthma in- 
creases (20). 
The aims of asthma therapy should be to acquire rapid 
control of the disease followed by maintained asthma 
control, and this should be achieved in a cost-effective 
manner. Much of the expenditure in poorly controlled 
asthma is avoidable. Thus, efforts must be made to en- 
courage physicians to follow treatment guidelines and to 
increase patients’ understanding and co-operation re- 
garding their prescribed therapy. 
Educating both physicians and patients about effective 
asthma management may reduce asthma costs (21,22). It is 
recognized that an essential element of enhanced asthma 
care is the formation of an effective partnership between 
the patient and the healthcare professional (22). Good 
communication is crucial in the management of asthma 
and a better doctor-patient relationship needs to be en- 
couraged, especially in primary care (23). Physicians 
need to gain as much information from the patient as 
possible so that the most effective therapy can be ap- 
plied. 
The asthma guidelines emphasize the importance of 
patient self-management combined with regular phys- 
ician review (5-8). This approach relies on the 
physicians’ ability to give their patients the necessary 
knowledge, skills and attitudes to control their asthma 
symptoms and to be able to recognize and cope with 
any changes in their condition.This can be achieved using 
specific educational programmes and there is growing 
evidence that self-management and educational pro- 
grammes in asthma are cost-effective (22,24). For exam- 
ple, in the USA, intervention with a self-management 
training programme, costing US$85/person, resulted in 
a significant reduction in emergency room costs from 
US$lO36 to US$408 per person per year (d=US$628; 
P=O .02) (25). Thus, training programmes are seen as a 
cost-effective way of reducing the overall burden on the 
healthcare service. 
COST-EFFECTIVE THERAPY FOR 
ASTHMA: FOCUS ON SYMBlCORT@ 
When considering the cost-effectiveness of inhaled cor- 
ticosteroids, there are four important issues to take into 
account: 
I. need for long-term daily treatment; 
2. adverse effects; 
3. adherence to prescribed medication; 
4. cost of inhaler devices. 
First, asthma is a chronic disease that requires long- 
term daily anti-inflammatory treatment. Inhaled corti- 
costeroids are the most effective controller medication 
for asthma, and a reduction or discontinuation of inhaled 
corticosteroids can cause asthma exacerbations even in 
patients with mild asthma (26,27). Thus, the costs of in- 
haled glucocorticosteroid treatment are likely to be life- 
long costs. Nevertheless, inhaled corticosteroids do not 
cure asthma; rather, they simply help control asthma by 
exerting a range of anti-inflammatory effects (28). Re- 
cent studies have indicated that if treatment with inhaled 
corticosteroids is started early in the course of the dis- 
ease, they may protect against the development of irre- 
versible structural changes and progressive deterio- 
ration in lung function that occurs over time (29). As a 
result, there is a trend towards greater and earlier use 
of inhaled corticosteroids in patients with milder disease. 
The second important issue is adverse effects. Those 
associated with inhaled corticosteroids are minor and 
usually do not require additional treatment (30). This is 
in contrast to oral steroids which, despite being low-cost 
drugs, can cause adverse effects that incur additional 
costs. Furthermore, because inhaled corticosteroids 
help control asthma, they can reduce the pain and suffer- 
ing associated with asthma and improve patient quality 
of life (31). Consequently, there may be a reduced need 
for extra medication to control other complications, 
such as anxiety and depression. 
The next issue is one of adherence to prescribed medi- 
cation; for inhaled glucocorticoids to be effective and/or 
cost-effective, patients must take them. Unfortunately, 
adherence to prescribed medication is poor, especially 
inhaled corticosteroids (18). Although there may be 
many reasons for this (see later) (32) fear of possible 
side-effects is a major reason that patients give for not 
taking their inhaled corticosteroids (33). Various ap- 
proaches can be taken to try to improve adherence: for 
example, educating the patients about asthma and its 
management, making inhalers more ‘user-friendly’ and 
providing the patients with more effective medication. 
For drugs with a rapid onset of effect which offer rapid 
relief from asthma symptoms, adherence to prescribed 
medication is likely to be higher than when there is no 
perceived effect on breathing (34). Thus the addition of 
formoterol, with its rapid onset of effect, to budesonide 
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in a single inhaler may improve adherence to prescribed 
medication. 
The final key issue when considering the cost-effec- 
tiveness of asthma therapy is the differences in cost of 
the various devices used to administer inhaled cortico- 
steroids. Dry powder inhalers are more expensive than 
pressurized metered dose inhalers (pMDls) in some 
countries (e.g. the UK), but are less expensive in others 
(e.g. Canada). It has been shown that budesonide delivered 
via Turbuhaler@ is more cost-effective than budeson- 
ide delivered via a pMDl (35). Moreover, the dry powder 
inhalers are breath-activated and easier to use than the 
pMDls. 
In asthma patients who remain inadequately con- 
trolled on inhaled corticosteroids, guidelines recom- 
mend an increase in the dose of inhaled corticosteroids 
or addition of a long-acting &agonist (5-8). Recent stud- 
ies indicate that adding a long-acting j&-agonist is not 
only more effective than using inhaled corticosteroids 
alone, but is also more cost-effective. In economic evalu- 
ations of asthma, cost-effectiveness is often assessed 
using a composite outcome measure-the symptom- 
free day or the episode-free day (also called the asthma 
control day) (36). A symptom-free day is defined as no 
night-time awakening and a night and a day with no 
symptoms (i.e. a symptom score = 0), while an episode- 
free day is defined as a night and a day without symp- 
toms, no intake of reliever medication and no asthma-re- 
lated night-time awakenings. 
Several randomized studies have demonstrated both 
the efficacy and cost-effectiveness of budesonide when 
given to patients previously taking short-acting pz- 
agonists alone (37-39). However, increasing the dose of 
budesonide from 400 to 800pgday-’ increased drug 
costs by 33% without resulting in increased efficacy in 
the short term, suggesting that this approach is not 
cost-effective (40). Since the use of combination therapy 
will increase direct costs of medication even further, it is 
important to determine whether combination therapy 
decreases healthcare service costs elsewhere by improv- 
ing asthma control. In other words, the focus in treating 
asthma patients should be on gaining and then maintain- 
ing control of asthma and not just on the actual cost of 
the medication itself. 
In the study by Pauwels and colleagues (4l), the addi- 
tion of the long-acting Pz-agonist formoterol to low- 
dose or high-dose budesonide for I year improved asthma 
symptoms and lung function in patients with moderate 
asthma compared with budesonide treatment alone. 
Indeed, the use of this combination, administered via 
separate inhalers, decreased the incidence of mild and 
severe asthma exacerbations (41) and in a separate study 
the same combination did not mask increasing airways 
inflammation (42). Furthermore, sustained improve- 
ments in patient quality of life were also achieved with 
this combination of formoterol and budesonide (43). An 
economic assessment of the costs of adding formoterol 
to budesonide found that although there are higher pre- 
scribing costs, these are more than offset by reduced 
costs associated with mild or severe exacerbations or 
loss of productivity (19). Thus, adding formoterol to bu- 
desonide not only improves control of asthma but is also 
cost-effective and even cost-saving in the long term. 
Further developments have been made such that bu- 
desonide and formoterol have now been combined to- 
gether in a single, modified Turbuhale? inhaler 
(Symbicort@ Turbuhaler”). The efficacy and safety of 
Symbicort@ have been studied in a l2-week, rando- 
mized, double-blind, active-controlled, multicentre trial 
performed in six European countries in 362 adult pa- 
tients whose asthma was not adequately controlled with 
inhaled glucocorticosteroid treatment alone (44). The 
patients were treated twice-daily with Symbicort@ 
(budesonide/formoterol 160/4’S pg; two inhalations); 
budesonide (200 ,ug; two inhalations) and formoterol 
(4.5 pg; two inhalations) via separate inhalers; or budeson- 
ide (2OOpg; two inhalations) alone (44). In an extension 
to this study, a health economic analysis has been per- 
formed comparing the SymbicortO group (n= 123) with 
the budesonide alone group (n=l24), and was conducted 
on the basis of the healthcare system and drug costs in 
Sweden with costs being calculated in SEK (45). 
The results of this study showed that Symbicort@ was 
more effective than budesonide alone; patients receiving 
Symbicort@ had 45 asthma control days (i.e. no noctur- 
nal waking, no asthma symptoms and no rescue medi- 
cation) over I2 weeks of treatment compared with 29 
asthma control days in patients receiving budesonide 
alone - a significant difference of 54% in favour of 
Symbicort@ (45). Furthermore, there were significantly 
fewer mild exacerbations in the Symbicort@ group than 
the budesonide alone group, with a trend in favour of 
Symbicort@ . In the number of severe exacerbations. 
Although the cost of Symbicort@ was higher than the 
cost of budesonide, the costs due to exacerbations and 
use of other asthma medications were lower in the Sym- 
bicort@ group compared with those for patients treated 
with budesonide alone. For example, the mean exacer- 
bation cost per patient during the l2-week study period 
was SEK 476 in the Symbicort@’ group compared with 
SEK 641 in the budesonide group (45). These results, i.e. 
the greater number of asthma control days and the lower 
cost of exacerbations in the Symbicort@ group, suggest 
that combined therapy of budesonide and formoterol in a 
single inhaler helps control asthma and is more cost-ef- 
fective than budesonide alone. 
ASTHMA AND THE PATIENT 
Appropriate and cost-effective treatment of asthma is 
very important, but so too is the well-being of the 
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patient. Asthma can be quite distressing to the sufferer, 
with some patients feeling that they cannot partake in 
‘normal’ activities such as exercise as a result of their 
asthma. Additionally, patients may experience anxiety 
caused by the fear of having an asthma attack (46). The 
misery associated with asthma can manifest itself in 
many ways, leading to a loss in productivity and embar- 
rassment, as is the case with cough-variant asthma 
where the coughing associated with this type of asthma 
can be so severe as to cause incontinence, insomnia and a 
disturbed social life (47). 
One of the aims of asthma treatment as outlined in 
the guidelines is that patients should have no restrictions 
on their ability to perform normal daily activities (physi- 
cal, social and occupational). Healthcare professionals 
should be particularly concerned about the normal devel- 
opment of asthmatic children, both mentally and phys- 
ically (6). They should use treatments that will control 
the child’s asthma to such an extent that they can have a 
normal lifestyle that is no different from that of their 
peers. Over the past decade, asthma-specific question- 
naires that assess the effects of various treatments on 
patient quality of life have been developed and validated 
(48). As part of the recent study by Pauwels and collea- 
gues, the long-term effects of inhaled corticosteroids 
and long-acting /Iz-agonists on asthma-specific quality 
of life were examined in 470 adults with asthma (43). 
After a 4-week run-in period during which they received 
budesonide (1600 ,ug day-‘), patients were randomized to 
budesonide (200 pg day-’ or 800 lug day-‘) in combina- 
tion with formoterol (24 ,ug day-‘) or placebo for I year. 
The Asthma Quality of Life Questionnaire (AQLQ) was 
completed seven times during the l2-month period. 
There was a significant improvement in the overall 
AQLQ score during the run-in period of approximately 
0.50 (P<O OOOI), and a further significant improve- 
ment of 0.21 (P=O ,028) in the budesonide (800 pug) plus 
formoterol (24,ug) group after randomization (43). The 
conclusion from this study was that the quality of life of 
an asthma patient may improve as a result of combined 
long-term therapy with budesonide and formoterol. 
These improvements will only occur if patients con- 
tinue to take their medication in the long term. Adher- 
ence to medication is a major factor determining the 
degree of asthma control. Unfortunately, adherence is 
poor worldwide, with fewer than 50% of asthma 
patients in some countries adhering to their recom- 
mended treatment regimen (18,49). The reasons behind 
this are complex, but may include: a lack of understand- 
ing or denial of their disease; confusion about treat- 
ments, especially when multiple inhalers are prescribed 
using different dosing frequencies; fear of side-effects 
from medications; poor doctor-patient communication; 
forgetfulness or complacency; psychological disorders 
such as depression; difficulties using the inhaler(s) pre- 
scribed (32,50-53). 
In a survey carried out on young asthmatics, 9% (4/45) 
admitted that lack of adherence was a result of problems 
they had with using their inhaler devices and the main 
reason for non-compliance was forgetfulness (53%, 
24/45) (32). Studies investigating patients’ ability to use 
inhalers have demonstrated that many patients do not 
use pMDls correctly; they cannot co-ordinate actuation 
of the device with inhalation (54). Asthma inhalers must 
be simple to use in order to maximize patient adherence 
to treatment. Dry powder inhalers are driven by inspira- 
tory flow and can be used by almost all asthmatics aged 
older than 5 years. A direct comparison of theTurbu- 
hale@ and Diskhaler@ systems for delivery of asthma 
medication, in an open, randomized, crossover study in 
adult patients, showed that theTurbuhaler@ is at least as 
effective and easy to use as the Diskhaler@ (53). Further- 
more, in other studies comparing theTurbuhaler@ and 
Diskus@ inhaler, more than 50% of patients (both adults 
and children) stated they were happy using theTurbu- 
hale? and would use it again (55,56). The simplification 
of asthma treatment regimens, such that patients are 
given perhaps only a single inhaler that they only have 
to use once or twice daily, is expected to have a signifi- 
cant impact on patient adherence and, therefore, on the 
control of the disease (57). 
SUMMARY 
Asthma imposes a significant burden on society as a 
whole and on individuals by reducing their well-being 
and quality of life. In addition, as the economic burden of 
asthma is increasing, efforts must be made to use the 
most cost-effective treatments available. Effective man- 
agement of asthma involves optimizing asthma control. 
Inhaled corticosteroids, such as budesonide, effectively 
control airways inflammation in asthma. Addition of an 
inhaled, long-acting flz-agonist, such as formoterol, to 
the existing anti-inflammatory treatment is an attractive 
option that may be beneficial to the patient by improving 
their asthma control and quality of life. Symbi- 
cart@-budesonide and formoterol in a single inhaler- 
is a cost-effective treatment for asthma vs budesonide, 
that quickly gains and maintains control of asthma. 
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